ReviewArchives of microbiology2026
The gut microbiome axis: how Lactobacillus-fermented soymilk orchestrates health.
Review in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Human culinary traditions have been deeply rooted in the consumption of fermented food products, offering health-promoting benefits. Among these, soymilk fermentation by lactic acid bacteria emerges as a captivating opportunity to produce enhanced soy-based flavor profiles with extended nutritional value. Among the numerous advantages, components of soymilk, such as isoflavone aglycones and peptides, show a hypolipidemic effect, thus proving beneficial to humans. Of central interest is Lactobacillus, a well-studied probiotic genus that exerts a pivotal role in the maintenance of gut barrier and microbial diversity. The interplay between gut microbiome and host physiology underscores its role in health and disease. Gut dysbiosis results from the interaction of environmental cues with host metabolic state, triggering pathological consequences. These range from irritable bowel syndrome and gastric cancer to neurological disorders. This review attempts to evaluate the knowledge surrounding fermented soymilk to shed light on the vital role of Lactobacillus in restoring a dysbiotic state within the gut microbiome. Further, we elucidate multifaceted mechanisms underlying the therapeutic potential of Lactobacillus-fermented soymilk. By exploring this complex interplay of microbial metabolites and host immune responses, and incorporating recent advancements in probiotic therapeutics, we emphasize the utilization of Lactobacillus-fermented soymilk as a dietary intervention to promote gut health and alleviate disease states.
Indexed as
Identifiers
41989563What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.